Dr. Alejandro D. Chediak, MD

Dr. Chediak practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Chediak's NPI, 1669401774, was assigned on July 1, 2006. Dr. Chediak graduated from Ross University School of Medicine in 1980. Dr. Chediak holds Florida license ME51163.

Dr. Chediak's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Chediak's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Chediak is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Chediak to 1 more hospital and 2 physician offices, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chediak practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Chediak's primary specialty in the NPI Registry, under taxonomy code 207RS0012X. The record also lists sleep medicine. Dr. Chediak is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Chediak's licenses on file in 2 states: Florida and Louisiana.

CMS data shows 689 Medicare services from Dr. Chediak across 7 procedure codes in 2024, for 456 Medicare patients. Medicare paid $42,536 for them.

CMS counts 456 Medicare patients who saw Dr. Chediak in 2024. The largest group is 65 to 74, with 186 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chediak's median patient age at 70, with 41% women.

In 2024, Dr. Chediak wrote 470 Medicare Part D claims for 116 patients. 76% of them were for generic drugs. CMS names the drug for 387 of them, across 14 drugs with 11 or more claims each, at $41,594 in total drug cost. In 2023, CMS named 305 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Chediak for performance year 2024, reported as part of a group. Dr. Chediak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chediak as offering telehealth.

Dmand AI links 36 papers to Dr. Chediak, published from 2014 to 2023. 2021 was the busiest year, with 2. The most frequent topics are Mucous Membrane, Sheep and Regional Blood Flow. Dr. Chediak has published most often in J Appl Physiol (1985). Dr. Chediak's most frequent co-authors are Alexandre R. Abreu, MD, Horst J. Baier, MD and Mehmet Cuneyt Demirozu, MD.

CMS Open Payments shows 95 general payments to Dr. Chediak from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. Jazz Pharmaceuticals Inc. paid the most, $8,293.

Dmand AI lists 1 award for Dr. Chediak.

Dr. Chediak graduated from Ross University School of Medicine in 1980.

Dr. Chediak is in network with 11 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.